Multiple Myeloma

P1, N=60, Not yet recruiting, C4 Therapeutics, Inc.

P1, N=31, Completed, Fate Therapeutics | Active, not recruiting --> Completed

P=N/A, N=13, Terminated, Institut Cancerologie de l'Ouest | Phase classification: P1/2 --> P=N/A

P1, N=10, Not yet recruiting, Xuzhou Medical University

Furthermore, LeukoPrint genome-wide profiling further revealed distinct CNA patterns between hyperdiploidy and non-hyperdiploidy, informing biological heterogeneity. In conclusion, LeukoPrint significantly outperforms conventional karyotyping and closely matches FISH for crucial CNA markers, offering an alternative for cytogenetic profiling and prognostic stratification in MM.

From the high rate of poor outcomes evident in our series, we propose that wide local excision, postoperative adjuvant radiotherapy and follow-up imaging surveillance are justified. However, further studies are now required to better establish treatment guidelines for this rare aggressive adnexal tumour.

A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses.

P1, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025

In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.

These findings provide novel insights into molecular landscape of SBP, highlighting potential for risk stratification and targeted therapy development. The case underscores the importance of comprehensive genomic profiling in rare skull-based tumors to enhance our understanding of their biology and to guide personalized clinical management.

This disruption results in enhanced accumulation of protein aggregates, increased protein polyubiquitination, endoplasmic reticulum stress, and activation of apoptotic pathways. Collectively, our findings support the repurposing of ceritinib in combination with carfilzomib as a translationally relevant and safe strategy to circumvent PI resistance in MM, warranting further clinical investigation in the relapsed/refractory disease setting.